Article
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
European journal of medicinal chemistry - 15 Mar 2020
Chen Yun, Bai Gang, Ning Yi, Cai Shi, Zhang Tao, Song Peiran, Zhou Jinpei, Duan Wenhu, Ding Jian, Xie Hua, Zhang Huibin
Abstract excerpt
Harboring MYD88 L265P mutation triggers tumors growth through the activation of NF-κB by interleukin-1 receptor associated kinase 4 (IRAK4) in diffuse large B-cell lymphoma (DLBCL), highlighting IRAK4 as a therapeutic target for tumors driven by aberrant MYD88 signaling. Herein, we report the design, synthesis, and structure-activity relationships of imidazo[1,2-b]pyridazines as potent IRAK4 inhibitors. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.